scispace - formally typeset
L

Luigi Naldini

Researcher at Vita-Salute San Raffaele University

Publications -  370
Citations -  59320

Luigi Naldini is an academic researcher from Vita-Salute San Raffaele University. The author has contributed to research in topics: Genetic enhancement & Viral vector. The author has an hindex of 108, co-authored 345 publications receiving 55080 citations. Previous affiliations of Luigi Naldini include Università telematica San Raffaele & Sangamo BioSciences.

Papers
More filters
Journal ArticleDOI

729. Inheritable Silencing of Endogenous Gene by Hit-and-Run Targeted Epigenetic Editing

Angelo Amabile, +5 more
- 01 May 2016 - 
TL;DR: A novel modality of gene silencing that exploits epigenetics to achieve stable and highly efficient repression of target genes is developed and provided the first demonstration of efficient and stable epigenetic silencing of endogenous genes upon transient delivery of ATRs.
Journal ArticleDOI

Phosphotyrosine antibodies identify the p210c-abl tyrosine kinase and proteins phosphorylated on tyrosine in human chronic myelogenous leukemia cells.

Luigi Naldini, +5 more
- 01 May 1986 - 
TL;DR: Probed on human leukemia cell lines, phosphotyrosine antibodies recognized a 210,000-molecular-weight protein (p210) in K562 cells, a cell line derived from a Philadelphia (Ph)'-positive chronic myelogenous leukemia (CML), but recognized no protein in control Ph'-negative non-CML leukemia cells.
Journal ArticleDOI

Reprogramming T Lymphocytes for Melanoma Adoptive Immunotherapy by T-Cell Receptor Gene Transfer with Lentiviral Vectors

Sara Bobisse, +10 more
- 15 Dec 2009 - 
TL;DR: The results indicate that lentiviral vectors represent a valid tool for stable and high-intensity expression of transgenic TCR and support clinical exploitation of this approach for therapeutic application.
Journal ArticleDOI

Transcriptional Targeting of Lentiviral Vectors by Long Terminal Repeat Enhancer Replacement

Francesco Lotti, +6 more
- 15 Apr 2002 - 
TL;DR: A critical advantage of this targeting strategy is the use of a spliced, major viral transcript to express a therapeutic gene and that of an internal, independently regulated promoter to express an additional gene for either cell marking or in vivo selection purposes.
Journal ArticleDOI

NY-ESO-1 TCR single edited stem and central memory T cells to treat multiple myeloma without graft-versus-host disease.

Sara Mastaglio, +24 more
- 03 Aug 2017 - 
TL;DR: When infused in NSG mice previously engrafted with myeloma, SE cells mediated tumor rejection without inducing xenogeneic graft-versus-host disease, thus resulting in significantly higher survival than that observed in mice treated with TR cells.